How to Value an ABA Therapy Practice: What Buyers Actually Pay

ABA therapy practices are currently selling for 4x to 7x EBITDA — with the top-quartile practices commanding 6x or higher from private equity platform buyers. The spread between a 3.5x deal and a 6.5x deal on the same revenue base can represent millions of dollars. Understanding exactly where your practice falls on that spectrum, and why, is the most important thing you can do before entering any M&A process.

This guide breaks down the valuation framework buyers actually use — not theoretical finance, but the specific factors that PE roll-ups and strategic acquirers are underwriting today.

Why ABA Therapy Attracts Premium Valuations

The behavioral health M&A market has shifted structurally over the last decade. ABA therapy, once a fragmented cottage industry, has become one of the most actively consolidated sub-verticals in healthcare services. The reason is simple: ABA has what acquirers want.

Mandated insurance coverage. All 50 states now require commercial insurers to cover ABA therapy for autism spectrum disorder. This mandate created a reimbursable, scalable service line that institutional capital could underwrite.

Chronic demand-supply imbalance. Waitlists at quality ABA practices routinely run 6–18 months. Buyers aren’t acquiring into a saturated market — they’re acquiring scarcity.

Recurring, long-duration client relationships. The average ABA client receives services for 2–4 years. That’s a revenue durability profile that most outpatient healthcare businesses can’t match.

Scalable clinical model. The BCBA-supervised RBT model allows for meaningful leverage ratios — one BCBA supervising 6–10 RBTs — which creates margin expansion potential that PE platforms can engineer.

These structural factors underpin the premium. But they also mean buyers are highly sophisticated about what they’re buying — and they know exactly what risk factors to discount.

See current EBITDA multiples by sub-vertical

The 5 Factors That Drive ABA Practice Valuation

1. BCBA Staff Retention and Pipeline

Nothing kills an ABA deal faster than BCBA concentration risk. If your practice runs on 2–3 BCBAs and one of them leaves, your clinical capacity — and your revenue — can drop 30% overnight. Buyers know this. They underwrite it heavily.

Practices that command 6x+ EBITDA typically have:

• 6 or more credentialed BCBAs on staff
• An internal BCBA pipeline (RBTs pursuing board certification)
• Average BCBA tenure of 2+ years
• Non-compete and retention agreements in place for key clinical staff
• A clinical director role that doesn’t depend on the owner

Conversely, practices where the owner is the primary BCBA — what brokers call “owner-operator clinical dependency” — will struggle to get above 4x. Buyers cannot pay a premium for a practice where the primary clinical asset walks out the door at closing.

2. Payer Mix and Reimbursement Quality

Not all ABA revenue is equal. A practice billing primarily to commercial insurance at $18–$22 per unit is a fundamentally different business than one relying on Medicaid at $10–$14 per unit — and buyers price that difference explicitly.

Commercial-dominant payer mix (70%+ commercial): Premium multiple territory. Commercial rates are higher, collection cycles are shorter, and margin profiles are stronger.

Medicaid-heavy payer mix (50%+ Medicaid): Buyers will still acquire, but expect a 0.5x–1.5x multiple discount depending on state rates and rate-change history. Some PE platforms specifically avoid high-Medicaid books.

Single-payer concentration: If 40%+ of your revenue runs through one commercial payer (a single BCBA insurance contract), buyers will flag this as concentration risk. Diversified panels across 5+ payers is the target profile.

3. Geographic Density and Market Position

PE roll-up platforms aren’t just buying practices — they’re buying market positions. Geographic density within a metro or regional market allows acquirers to build referral network dominance, shared administrative infrastructure, and brand recognition that drives organic growth post-acquisition.

High-value scenarios for geographic factors:

• Located in a metro area with documented autism diagnosis rates above the national average (currently 1 in 36 per CDC, but metro variation is significant)
• Multi-site footprint within a defined geographic territory
• Proximity to pediatric neurology, developmental pediatrics, or early intervention referral sources
• Not in a market already heavily penetrated by the acquirer’s existing platform

4. Clinical Outcomes Data and Documentation

This factor is increasingly separating top-quartile valuations from mid-market deals. Sophisticated buyers — particularly PE-backed platforms with clinical leadership — are now asking for outcomes data as part of due diligence.

What they want to see:

• VBMAPP or ABLLS-R progress data tracked systematically
• Goal mastery rates by client cohort
• Session note compliance rates (target: 95%+ on-time)
• No outstanding HIPAA violations, Medicaid audits, or payer recoupment demands
• Staff supervision documentation that meets BACB standards

Practices with robust outcomes data can support a clinical quality narrative that justifies premium pricing. Practices with documentation gaps are acquiring liability exposure that buyers will price into their offer — or use as a retrade lever post-LOI.

5. Revenue Size, Growth Trajectory, and Margin Profile

Buyers apply different frameworks at different revenue scales:

Growth trajectory matters as much as current EBITDA. A practice growing 25% year-over-year will command a forward-multiple that a flat practice cannot. Buyers will often pay on a “next twelve months” EBITDA projection for high-growth practices, which can meaningfully change deal economics.

Margin profile benchmark: EBITDA margins of 15–25% are typical for well-run ABA practices. Margins below 10% will invite heavy scrutiny; margins above 25% will generate competitive interest.

Learn what drives valuation across all behavioral health sub-verticals

What PE Roll-Up Buyers Are Actually Looking For

Private equity has driven the ABA M&A market for the last 7 years and continues to be the dominant buyer class. Understanding PE acquisition criteria specifically — not just generic M&A logic — changes how you should think about positioning your practice.

Platform vs. Add-on dynamics. PE firms build platforms by acquiring a larger “platform” practice (often $5M+ revenue) and then bolting on smaller “add-on” acquisitions. Add-ons typically receive lower multiples than platform practices, but the calculus can shift if you’re a highly strategic add-on in a specific geography the platform needs to fill.

EBITDA normalization. Buyers will recast your financials. Owner compensation above market rate gets added back. One-time expenses get added back. But so does any management infrastructure you haven’t built yet — and that will be a deduction. The cleaner your books, the cleaner the recast.

Quality of earnings (QofE) diligence. Most PE buyers require a third-party QofE analysis before closing. This process scrutinizes revenue recognition, client concentration, payer aging, and staff costs. Preparing your financials for QofE scrutiny before going to market will save you from retrade surprises.

Earnouts and rollover equity. Many ABA deals include an earnout component tied to 12–24 month post-close revenue or EBITDA targets. PE platforms also frequently offer sellers the opportunity to roll 15–30% of deal proceeds into equity in the acquiring platform — a “second bite of the apple” that has historically generated significant value for sellers who chose it wisely.

Red Flags That Suppress ABA Practice Valuations

Before going to market, address these known valuation suppressors:

• Medicaid billing audits or recoupments: Even resolved audits create disclosure obligations and buyer anxiety. Clean this up before engaging buyers.
• BACB complaints against clinical staff: These create licensing risk that buyers will price heavily.
• Lease expiration within 12 months: Buyers need facility continuity. Renew leases before going to market, or negotiate assignment rights explicitly.
• Revenue decline in the trailing twelve months: Even temporary dips require explanation. A clean, upward growth trajectory is worth preparing for.
• Client concentration: If any single client represents more than 10% of revenue, buyers will flag it. Not a deal-killer, but it will impact pricing.

Frequently Asked Questions: ABA Therapy Practice Valuation

What EBITDA multiple should I expect for my ABA therapy practice?

Most ABA therapy practices sell for 4x to 7x EBITDA in today’s market. The specific multiple depends on practice size, BCBA staff depth, payer mix, geographic market, and growth trajectory. Practices with $8M+ revenue, strong commercial payer mix, and retained clinical leadership regularly command 6x or higher.

How is EBITDA calculated for an ABA therapy practice?

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. For ABA practices, buyers typically start with net income and add back owner compensation above market rate, personal expenses run through the business, one-time costs, depreciation on equipment, and any non-recurring items. This “normalized” or “adjusted” EBITDA is the figure used for valuation.

Does payer mix really affect the sale price of my ABA practice?

Yes — significantly. Commercial insurance payers reimburse at materially higher rates than Medicaid, which directly impacts EBITDA and therefore the dollar value of any given multiple. A practice with 70%+ commercial revenue can often command a 0.5x–1x multiple premium over an equivalent-sized Medicaid-heavy practice.

What happens to my BCBAs when I sell my practice?

Most acquirers — especially PE platforms — are deeply focused on retaining clinical staff post-close. Many deals include retention bonuses funded by the buyer for key BCBAs. As the seller, your ability to secure staff commitments prior to closing is a significant value driver. Buyers who see staff retention risk will discount accordingly.

How long does it take to sell an ABA therapy practice?

A well-prepared ABA practice sale typically takes 6–12 months from initial market preparation through closing. This includes 4–8 weeks of preparation, 8–12 weeks of buyer outreach and LOI process, and 60–90 days of due diligence and closing. Practices with clean financials and organized documentation tend to close faster and with fewer retrade events.

Do I need a broker to sell my ABA therapy practice?

You don’t legally need one, but the data strongly favors using an M&A advisor with behavioral health experience. Advisors with direct ABA transaction history know which buyers are active, what market multiples look like in real time, and how to structure a competitive process that prevents any single buyer from dictating terms.

Can I sell part of my ABA practice and retain an ownership stake?

Yes. Many PE transactions are structured as partial recapitalizations, where the seller receives a cash payout for a majority stake while retaining 15–40% equity in the recapitalized business. This structure lets owners take liquidity now while remaining positioned to benefit from the platform’s continued growth and a future exit.

See how ABA multiples compare to other behavioral health segments

Understand the full process of selling a behavioral health practice